Survey
Quarterly Survey: PSMA PET Imaging Agents Trends and Preferences - October 2023
Ticker(s): LNTH, NVS, Telix, Blue Earth DiagnosticsSurvey results include 20 Oncologists.
How many mCRPC patients do you see per month, on average?
How would you best describe your practice?
- Academic
- Community
- Private
How would you describe the size of your practice?
Which of the following describes your practice?
How does your PSMA-PET imaging volume compare with 6 months ago?
How do you anticipate your PSMA-PET imaging volumes to change over the next 6 months?
How are you currently distributing your usage among the following PSMA-PET imaging agents? Please indicate 0-100 for each, must sum to 100%.
- Pylarify
- Illuccix
- Posluma
- Locametz
- Other
Please offer insights into the distribution usage in your previous response and explain what factors influenced your choice of the preferred agent or agents?
Do you currently use or plan to use PSMA-PET imaging off-label (for disease monitoring or earlier stage patients)?
How do you expect your usage among the following PSMA-PET imaging agents to be in 1 year? Please indicate 0-100 for each, must sum to 100%.
- Pylarify
- Illuccix
- Posluma
- Locametz
- Other
Please offer insights into the distribution usage in your previous response and explain what factors influenced your choice of the preferred agent or agents.
How frequently are PSMA PET scans repeated (in terms of months) for patients undergoing PSMA-directed therapy as part of their treatment follow-up, excluding the initial diagnostic scan?
How will expiration of pass through payment affect your center's use of Pylarify?
What do you see as the main difference between Pylarify and Posluma (if any)?
How many patients have you started on Pluvicto (Novartis Lu-PSMA-617) in the commercial setting (excluding patients treated on clinical trials)?
Given the recently released PSMAFore results (Lu-PSMA-617), how do you expect the number of patients treated with PSMA-directed therapy to change?
And considering the recently released PSMAFore results (Lu-PSMA-617), to what extent do you anticipate the number of patients treated with PSMA-directed therapy will change? Please answer in percentage change % (positive or negative, or 'NA' if stable).
If Pluvicto (Lu-PSMA-617) and PNT-2002 (Lu-PSMA-I&T) were both approved for 2L mCRPC with comparable outcomes, how do you expect to distribute your usage between these two products? Please indicate 0-100 for each, must sum to 100.
- Pluvicto (Lu-PSMA-617)
- PNT-2002 (Lu-PSMA-I&T)
Regarding the previous response, please explain your breakdown.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
